Ceftaroline Fosamil

China [CN]

Applications and Clinical Information (Core for International Trade/Customer Communication)

1. Core Applications

Approved Indications (all for intravenous administration):

Acute Bacterial Skin and Soft Tissue Infections (ABSSSI) (including MRSA)

Community-Acquired Bacterial Pneumonia (CABP) (including drug-resistant Streptococcus pneumoniae)

Mechanism: The prodrug is rapidly converted to ceftaroline in the body by phosphatases, inhibiting cell wall synthesis by binding to PBPs; its unique binding to PBP2a provides anti-MRSA activity; it also covers common community-acquired Gram-negative bacteria, making it a first-line choice for severe community-acquired infections.

2. Key Clinical Information

Dosage Form: Sterile powder for injection (500mg, 1000mg, calculated as ceftaroline)

Dosage and Administration: Adults 600mg every 12 hours, intravenous infusion over 5–60 minutes; dose reduction is required for patients with renal impairment (CrCl<50 mL/min)

Core Advantages:

Anti-MRSA: The first fifth-generation cephalosporin approved for anti-MRSA activity, the preferred choice for community-acquired MRSA infections

Broad-spectrum G+: Potent coverage of streptococci (including drug-resistant Streptococcus pneumoniae) and enterococci (partial)

Prodrug Design: Good water solubility, convenient intravenous administration, and rapid activation in the body

Community Applicability: Used for severe community-acquired infections, balancing efficacy and safety